Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1176

—

01c42efd-3571-5014-b4a0-e68241086ada

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.399
  • MYC_TARGETS_V1+0.356
  • OXIDATIVE_PHOSPHORYLATION+0.319
  • MITOTIC_SPINDLE+0.245
  • PEROXISOME+0.186
  • UV_RESPONSE_DN+0.177
  • NOTCH_SIGNALING+0.162
  • BILE_ACID_METABOLISM+0.161
  • WNT_BETA_CATENIN_SIGNALING+0.159
  • ANDROGEN_RESPONSE+0.157

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.413
  • TNFA_SIGNALING_VIA_NFKB-0.327
  • INFLAMMATORY_RESPONSE-0.326
  • ALLOGRAFT_REJECTION-0.324
  • IL6_JAK_STAT3_SIGNALING-0.307
  • ANGIOGENESIS-0.260
  • PANCREAS_BETA_CELLS-0.247
  • P53_PATHWAY-0.244
  • INTERFERON_GAMMA_RESPONSE-0.233
  • MYOGENESIS-0.225

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SJEPD030580_D1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.853
2MNG1053
mng-umap@100
——0.847
3MNG730
mng-umap@100
——0.839
4R370
bladder-landscape@3
——0.838
5SJEPD031010_D1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.838
6131546
medullo-epn-umap@date-based
EPNEPN Tumor0.837
7MNG1213
mng-umap@100
——0.832
8MDT-AP-0211
medullo-epn-umap@date-based
MedMedulloblastoma0.829
9SJEPD031078_D2.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.827
10SRR12202452
bladder-landscape@3
——0.814

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.399Remibrutinib— uncovered
MYC_TARGETS_V10.356Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.319Remibrutinib— uncovered
MITOTIC_SPINDLE0.245Inavolisib— uncovered
PEROXISOME0.186Idelalisib— uncovered
UV_RESPONSE_DN0.177Inavolisib— uncovered
NOTCH_SIGNALING0.162Inavolisib— uncovered
BILE_ACID_METABOLISM0.161Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.159Inavolisib— uncovered
ANDROGEN_RESPONSE0.157Inavolisib— uncovered
TGF_BETA_SIGNALING0.129Inavolisib— uncovered
HEME_METABOLISM0.117Temsirolimus— uncovered
UNFOLDED_PROTEIN_RESPONSE0.115Idelalisib— uncovered
DNA_REPAIR0.112Idelalisib— uncovered
UV_RESPONSE_UP0.108Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.099Inavolisib— uncovered
ADIPOGENESIS0.081Inavolisib— uncovered
G2M_CHECKPOINT0.051Inavolisib— uncovered
APICAL_SURFACE0.025Temsirolimus— uncovered
FATTY_ACID_METABOLISM0.020Inavolisib— uncovered